The EAGER funding mechanism may be used to support exploratory work in its early stages on untested, but potentially transformative, research ideas or approaches. This work may be considered especially "high risk-high payoff" in the sense that it, for example, involves radically different approaches, applies new expertise, or engages novel disciplinary or interdisciplinary perspectives.

EAGER grants can be a real stepping stone for researchers early in their careers or a good option for a project that is in the back of the mind of a mid-career investigator. These types of proposals are not reviewed externally. The program officer makes the decision based on internal review only, so connection with the program and program officer are key success factors. Your knowledge of the process and the sort of projects that get funded are crucial to developing a successful strategy.

Should you take your project down the EAGER pathway? Find out during this insightful webinar.
5 Key Take-Aways:

✓ How to develop an EAGER strategy
✓ The type of projects that are a good fit for EAGER
✓ Knowledge of the EAGER review process and mechanism for renewed funding
✓ Qualifying your proposal as high risk
✓ Examples of successful EAGER proposals

This Webinar is Perfect for PIs Who Want To:

✓ Know if their proposed research fits the EAGER criteria
✓ Determine if the proposed research does or does not “fit” into existing programs at the NSF
✓ Establish a connection with the program officer
✓ Identify focus areas aligned with NSF’s ideas of transformative research
✓ Scope the work and budget to fit NSF expectations
Michael Lesiecki, PhD, CRA, is the principal investigator for a large grant from the National Science Foundation’s Advanced Technological Education program. He has 27 peer-reviewed journal publications and a patent. He received his PhD in Physical Chemistry from Oregon State University. He was a Research Professor at the University of Utah and an Associate Professor at the University of Puerto Rico. At Exxon Research and Engineering, Dr. Lesiecki worked as a Senior Scientist and was the director of the Bioscience Division at Candela Laser Corporation. He authored successful SBIR proposals while at Candela, including six Phase I and five Phase II grants to the National Institutes of Health. Dr. Lesiecki left Candela to open Scion Scientific, with a Phase-I SBIR grant from the National Eye Institute.